These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. PPAR delta: a dagger in the heart of the metabolic syndrome. Barish GD; Narkar VA; Evans RM J Clin Invest; 2006 Mar; 116(3):590-7. PubMed ID: 16511591 [TBL] [Abstract][Full Text] [Related]
4. Activation of PPAR-δ induces microRNA-100 and decreases the uptake of very low-density lipoprotein in endothelial cells. Fang X; Fang L; Liu A; Wang X; Zhao B; Wang N Br J Pharmacol; 2015 Aug; 172(15):3728-36. PubMed ID: 25857370 [TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and structure-activity relationship study of peroxisome proliferator-activated receptor (PPAR) delta-selective ligands. Miyachi H Curr Med Chem; 2007; 14(22):2335-43. PubMed ID: 17896982 [TBL] [Abstract][Full Text] [Related]
7. PPAR delta as a therapeutic target in metabolic disease. Reilly SM; Lee CH FEBS Lett; 2008 Jan; 582(1):26-31. PubMed ID: 18036566 [TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptor-δ activates endothelial progenitor cells to induce angio-myogenesis through matrix metallo-proteinase-9-mediated insulin-like growth factor-1 paracrine networks. Han JK; Kim HL; Jeon KH; Choi YE; Lee HS; Kwon YW; Jang JJ; Cho HJ; Kang HJ; Oh BH; Park YB; Kim HS Eur Heart J; 2013 Jun; 34(23):1755-65. PubMed ID: 21920965 [TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptor-delta agonist enhances vasculogenesis by regulating endothelial progenitor cells through genomic and nongenomic activations of the phosphatidylinositol 3-kinase/Akt pathway. Han JK; Lee HS; Yang HM; Hur J; Jun SI; Kim JY; Cho CH; Koh GY; Peters JM; Park KW; Cho HJ; Lee HY; Kang HJ; Oh BH; Park YB; Kim HS Circulation; 2008 Sep; 118(10):1021-33. PubMed ID: 18711014 [TBL] [Abstract][Full Text] [Related]
11. Advances and Challenges in Drug Design of PPARδ Ligands. Maltarollo VG; Kronenberger T; Windshugel B; Wrenger C; Trossini GHG; Honorio KM Curr Drug Targets; 2018; 19(2):144-154. PubMed ID: 28413978 [TBL] [Abstract][Full Text] [Related]
12. Roles of peroxisome proliferator-activated receptor delta (PPARdelta) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome. Luquet S; Lopez-Soriano J; Holst D; Gaudel C; Jehl-Pietri C; Fredenrich A; Grimaldi PA Biochimie; 2004 Nov; 86(11):833-7. PubMed ID: 15589693 [TBL] [Abstract][Full Text] [Related]
13. Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor delta agonists. Epple R; Cow C; Xie Y; Azimioara M; Russo R; Wang X; Wityak J; Karanewsky DS; Tuntland T; Nguyêñ-Trân VT; Cuc Ngo C; Huang D; Saez E; Spalding T; Gerken A; Iskandar M; Seidel HM; Tian SS J Med Chem; 2010 Jan; 53(1):77-105. PubMed ID: 19928766 [TBL] [Abstract][Full Text] [Related]
14. Rationally designed PPARδ-specific agonists and their therapeutic potential for metabolic syndrome. Cox RL Proc Natl Acad Sci U S A; 2017 Mar; 114(13):3284-3285. PubMed ID: 28320957 [No Abstract] [Full Text] [Related]
17. [Doping in the next generation: wringing extra performance from the genotype]. Aumiller J MMW Fortschr Med; 2009 Mar; 151(12):12-4, 16. PubMed ID: 19475848 [No Abstract] [Full Text] [Related]
18. Peroxisome proliferator-activated receptor beta/delta: a new antihypertrophic drug target? Petrashevskaya NN; Schwarz A Cardiovasc Res; 2005 Mar; 65(4):770-1. PubMed ID: 15721856 [No Abstract] [Full Text] [Related]